<DOC>
	<DOCNO>NCT01714154</DOCNO>
	<brief_summary>This multi-center , fixed-sequence , open-label , multiple-dose , 2-period study evaluate safety , tolerability pharmacokinetics setrobuvir alone combination ritonavir-boosted danoprevir subject mild hepatic impairment compare healthy control . All subject receive multiple dos setrobuvir orally 10 day Period 1 multiple dos setrobuvir plus ritonavir-boosted danoprevir orally 10 day Period 2 , washout phase least 9 day treatment .</brief_summary>
	<brief_title>A Safety And Pharmacokinetic Study Setrobuvir Alone In Combination With Ritonavir-Boosted Danoprevir Subjects With Mild Hepatic Impairment Compared Healthy Controls</brief_title>
	<detailed_description />
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lactams</mesh_term>
	<criteria>Male female adult , 1865 year age , inclusive Weight &gt; /= 45.0 kg Body mass index ( BMI ) 18.0 35.0 kg/m2 , inclusive Females childbearing potential male female partner childbearing potential must agree use two form nonhormonal contraception define protocol Subjects history substance abuse may enrol provide abused drug alcohol least 6 month Healthy subject : Medical history without major recent ongoing pathology Laboratory value screen Day 1 within normal range show clinically relevant deviation Subjects hepatic impairment : Stable mild liver disease ( ChildPugh A ) cryptogenic , posthepatic , hepatitis B/C , alcoholic origin Stable hepatic impairment define clinically significant change disease status within last 30 day Must stable dose medication and/or treatment regimen least 2 week dose study medication Pregnant lactate woman male female partner pregnant lactate Active infection febrile illness &lt; /= 10 day prior first dose study medication Uncontrolled/untreated hypertension Inadequate renal function Positive urine drug screen positive breath alcohol test screen Day 1 period An average alcohol intake 2 unit per day 14 unit per week 48 hour prior enrollment History significant drugrelated allergy hepatotoxicity Participation clinical study investigational drug new chemical entity within 3 month ( 6 month biologic therapy ) prior first dose study medication Positive HIV infection Any clinically significant cardiovascular cerebrovascular disease Healthy subject : Any clinically significant concomitant disease condition could interfere , treatment might interfere , conduct study , absorption medication , would , opinion investigator , pose unacceptable risk subject study Positive screen test HBsAg HCV antibody Subjects hepatic impairment : Severe ascites screen Day 1 History current severe hepatic encephalopathy ( Grade 3 high ) Biliary liver cirrhosis cause hepatic impairment relate parenchymal disorder and/or disease liver Positive screen test HCV antigen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>